Sareum (SAR) returns 700% in a year: Is this small-cap share still a good buy?

Source: BlurryMe, Shutterstock Summary: UK's leading cell and gene therapy firm Oxford Biomedica reported a 37 per cent increase in its revenue to £87.7 million for FY20. PureTech’s operating losses shrunk from $135.39 million in 201...

Source: DSkorynko, Shutterstock Summary Although Coinbase made a smashing debuted on NASDAQ, opening 4% higher than the reference price, the Company had humble beginnings. Co-founders Fred Ehrsam and Brian Armstrong met on Reddit and built the...

Source: insta_photos, Shutterstock Summary J&J delays the distribution of its Covid-19 vaccine to Europe. US may not use the AstraZeneca vaccine, says the chief pandemic adviser to the White House. Pfizer is likely to meet its US supply t...

and concerns of using SGLT2 inhibitors to treat Covid-19 patients admitted to hospital. Things are not at all smooth for the pharma major AstraZeneca Plc (LON: AZN). After getting mired in various controversies related to its Covid-19 vaccine (...

Source: LookerStudio, Shutterstock Summary The European Medicines Agency has said that the benefits of using AstraZeneca vaccine outweigh the potential risks it had highlighted before.  The MHRA is also scheduled to come up with an up...

Source: Guschenkova, Shutterstock Summary On a YTD scale, healthcare stocks have multiplied the investors’ wealth by almost 2.5 times. Healthcare sector has a lot of ground to cover, and businesses can access a huge door of growth opport...

Source: insta_photos, Shutterstock Summary The UK authorities said that first jabs of Moderna vaccine would be rolled out in April. The Boris Johnson government had said that it was committed to its plans to vaccinate the entire adult populati...

Source: PhotobyTawat, Shutterstock Summary The Oxford-AstraZeneca vaccine is 76 per cent effective against the coronavirus infection. The earlier US clinical trial results had put the value a tad higher at 79 per cent. Despite the lower rate,...

Source: PhotobyTawat, Shutterstock Summary Shares of AstraZeneca have experienced a turbulent trading session of late. The stock was trading at GBX 7,133, up 0.07 per cent on 19 March. This year so far, the stock has largely fallen extending ...

Source: Aedka Studio, Shutterstock Summary AstraZeneca has recently faced suspensions from several countries and now is awaiting the EU medical watchdog’s official verdict. The company’s shares are still in the green as the World H...